Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors

被引：0
|
作者：
Tenaillon, Anne [1 ]
Orbach, Daniel [1 ]
机构：
[1] Inst Curie, Ctr Integre Soins & Rech Oncol Enfant Adolescent &, 26 rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 04期
关键词：
Inflammatory myofibroblastic tumor; Targeted therapy; ALK-positive; Crizotinib; Children;
D O I：
10.1016/j.bulcan.2022.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：248 / 249
页数：2
相关论文
共 50 条
  • [1] Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics
    Meurillon, Roxane
    Leruste, Amaury
    BULLETIN DU CANCER, 2023, 110 (03) : 250 - 251
  • [2] Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors
    Trahair, Toby
    Gifford, Andrew J.
    Fordham, Ashleigh
    Mayoh, Chelsea
    Fadia, Mitali
    Lukeis, Robyn
    Wood, Andrew C.
    Valvi, Santosh
    Walker, Roderick D.
    Blackburn, James
    Heyer, Erin E.
    Mercer, Tim R.
    Barbaric, Draga
    Marshall, Glenn M.
    MacKenzie, Karen L.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 11
  • [3] Use of crizotinib for refractory ALK-positive lymphomas
    Shelikhova, L. N.
    Fominykh, V. V.
    Abramov, D. S.
    Myakova, N. V.
    Maschan, M. A.
    Maschan, A. A.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 51 - 56
  • [4] Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor
    Kaino, Akira
    Niizuma, Hidetaka
    Katayama, Saori
    Irie, Masahiro
    Nakano, Tomohiro
    Sato, Daichi
    Saito, Tsuyoshi
    Kato, Shunsuke
    Suehara, Yoshiyuki
    Sasahara, Yoji
    Kikuchi, Atsuo
    PEDIATRIC BLOOD & CANCER, 2023, 70 (08)
  • [5] TWO PEDIATRIC CASES OF ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR OF THE PORTA HEPATIS
    Murakoshi, Yuka
    Oshima, Koichi
    Sugawa, Masahiro
    Mori, Makiko
    Fukuoka, Kohei
    Arakawa, Yuki
    Kawashima, Hiroshi
    Hosokawa, Takahiro
    Nakazawa, Atsuko
    Koh, Katsuyoshi
    PEDIATRIC BLOOD & CANCER, 2024, 71 : S66 - S67
  • [6] Pediatric ALK-Positive Inflammatory Myofibroblastic Tumors of The Head and Neck: Clinicopathologic Features with an Emphasis on Targeted Neoadjuvant Therapy
    Lopez-Nunez, Oscar
    Malik, Faizan
    Casiano, Carlos
    Berklite, Lara
    Breaux, Andrea
    Din, Nasir Ud
    Szabo, Sara
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1583 - S1584
  • [7] Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large celllymphoma
    Knoerr, Fabian
    Schellekens, Kim P. J.
    Schoot, Reineke A.
    Landman-Parker, Judith
    Teltschik, Heiko-Manuel
    Foerster, Jan
    Riquelme, Amambay
    Huitema, Alwin D. R.
    van Eijkelenburg, Natasha K. A.
    Beishuizen, Auke
    Zwaan, C. Michel
    Woessmann, Wilhelm
    van der Lugt, Jasper
    HAEMATOLOGICA, 2023, 108 (05) : 1442 - 1446
  • [8] Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors
    Lowe, Eric
    Mosse, Yael P.
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 247 - 255
  • [9] Crizotinib in ALK-positive lung cancer
    Girard, Nicolas
    LANCET ONCOLOGY, 2012, 13 (10): : 962 - 963
  • [10] ALK-Positive Inflammatory Myofibroblastic Tumor of the Abdomen With Widespread Microscopic Multifocality
    Lorenzi, Luisa
    Cigognetti, Marta
    Medicina, Daniela
    Pellegrini, Vilma
    Balzarini, Piera
    Cestari, Renzo
    Facchetti, Fabio
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2014, 22 (07) : 640 - 644
12345